Trade name : Cizumab
Active component : Bevacizumab
Strength availability : 400mg/16ml & 100mg/4ml
Manufactured by : Hetero
Package : 400mg of Bevacizumab containing vial


Category: Monoclonal antibody or Anti-angiogenesis drug Bevacizumab is sold under the brand name Cizumab which belongs to vascular endothelial growth factor directed antibody, the main ingredient which is used as bevacizumab. Cizumab consist of human framework regions and murine complementarity-determining regions. Cizumab is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF)


Cizumab is indicated for the treatment :
• In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice for Metastatic colon or rectal cancer
• Concurrent use with carboplatin and paclitaxel as first line therapy for Non-squamous, non-small cell lung cancer
• Used in the treatment of recurrent Glioblastoma in adults
• Concurrent use with interferon alfa for Metastatic renal cell cancer
• Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan for Metastatic cervical cancer
• In combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for Epithelial ovarian, fallopian tube or peritoneal cancer

Key point :
Avoid administrating Cizumab before at least 28 days following surgery and the wound is completely cured
Metastatic colorectal carcinoma :
The Cizumab usual dosage by concomitant with 5-fluorouracil based chemotherapy. Cizumab 5mg/kg for every 2 weeks IV in concomitant with bolus IFL Cizumab 10mg/kg for every 2 weeks IV in combination with FOLFOX4 Cizumab 5mg/kg IV for every 2 weeks or Cizumab 7.5 mg/kg as IV every 3 weeks by concurrently take with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy
Non-small cell lung cancer :
The patients regular dosage of Cizumab is 15mg/kg IV for every 3 weeks by interacting with carboplatin and paclitaxel
Glioblastoma :
Cizumab 10mg/kg administered IV for every 2 weeks
Metastatic renal cell cancer :
Concurrent use with interferon alfa.: The usual dose of Cizumab is 10mg/kg IV for every 2 weeks
Metastatic cervical cancer :
The usual dose of Cizumab; Cizumab 15mg/kg given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan
Epithelial ovarian, fallopian tube or peritoneal cancer :
The usual dose of Cizumab for Platinum opposing:; 10mg/kg of Cizumab for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The regular dosage of Cizumab; 15mg/kg of Cizumab given through IV for every 3 weeks by combining with topotecan The usual dose of Cizumab for Platinum responsive; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Cizumab; 15mg/kg of Cizumab given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles.


The pharmacokinetic form of Cizumab is assayed by measuring total serum Bevacizumab concentration.
Distribution :
The volume of distribution is 2.9 (22%) L
Elimination :
The terminal half life period of Bevacizumab is 20days (11 to 50days)


Cizumab constitute an active ingredient like Bevacizumab which joined to VEGF and will not have communication of VEGF to its receptors like Flt-1 & KDR that present on the surface of the cells. While this interaction inhibits endothelial cell proliferation and new blood vessel production occurs Hence in counts discontinuation of metastatic tumor cells growth happens


Cizumab is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Cizumab IV infusion is prepared in aseptic condition Cizumab 400mg containing 16ml solution whereas 100mg containing 4ml Cizumab dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Dispose the remaining drug which is left in a vial under guidance of pharmacist.


Caution with use in the conditions like ;
Previously If you have taking or ever had DPD (dihydropyrimidine dehydrogenase) deficiency of enzyme . Inform the doctor about this then your doctor may preferably inform you avoid taking Cizumab. Discuss with the doctor that you have or have ever had renal, hepatic, or cardiac problem Discuss with the doctor that are you pregnant or plan to become pregnant. Avoid planning to have children while on treatment with Cizumab. You should use a essential method of conceiving to prevent pregnancy in yourself or your partner during your treatment with Cizumab. The drug will harm the fetus. Avoid breast feeding while on treatment with Cizumab While using Cizumab these are some other complications occurred during therapy, care should be taken Hypertension Posterior reversible encephalopathy syndrome Gastrointestinal perforations Wound healing complications Hemorrhage Arterial thromboembolic events Venous thromboembolic events Embryo fetal toxicity occurs


If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose


Cizumab vial should be stored at 2 to 8℄ (36 to 46℃) Single use vial Discard the left out medicine under guidance of pharmacist


No contraindication occurred


While interaction of Cizumab with paclitaxel & Carboplatin, leads to lowering in exposure of paclitaxel after four cycles of therapy.


Gastrointestinal perforation and fistulae
Surgery and wound healing complication
Arterial thromboembolic events
Venous thromboembolic events
Posterior reversible encephalopathy syndrome
Renal injury & Proteinuria
Infusion reactions
Ovarian failure
Congestive heart failure
Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia.

We'd Like to Hear From You!


1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.